Holen Sie sich die Stockscreener-App
2.26
2.73%
0.06
Schlusskurs vom Vortag:
$2.20
Offen:
$2.24
24-Stunden-Volumen:
16,261
Relative Volume:
0.39
Marktkapitalisierung:
$1.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.07M
KGV:
-0.0555
EPS:
-40.717
Netto-Cashflow:
$-16.23M
1W Leistung:
-20.42%
1M Leistung:
-29.15%
6M Leistung:
-71.68%
1J Leistung:
-95.06%
1-Tages-Spanne:
$2.10
$2.31
1-Wochen-Bereich:
$2.0573
$2.7748
52-Wochen-Spanne:
$2.0573
$46.42
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Firmenname
Cns Pharmaceuticals Inc
Sektor
Branche
Telefon
1-800-946-9185
Adresse
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
2.29 | 1.36M | 0 | -13.07M | -16.23M | -40.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.58 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.28 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
683.54 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
310.64 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.96 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Eingeleitet | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Aktie (CNSP) Neueste Nachrichten
CNS Pharmaceuticals shifts focus to neurology, oncology assets By Investing.com - Investing.com Nigeria
Quarterly Trades: Is CNS Pharmaceuticals Inc currently under institutional pressure2026 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology - The Globe and Mail
CNS Pharmaceuticals shifts focus to neurology, oncology assets - Investing.com India
CNSP Implements New Strategy to Enhance Neurology and Oncology P - GuruFocus
CNS Pharmaceuticals Announces Strategic Shift to Neurology and Oncology Pipeline Expansion - citybuzz -
CNS Pharmaceuticals Launches Strategic Pivot Led by New Executive Team, Targeting High-Value Neurology and Oncology Assets for Investor Growth 123 - Minichart
CNS Pharmaceuticals (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology and Oncology Pipeline Expansion - Digital Journal
CNS Pharmaceuticals launches strategic pivot, names new executive team and begins asset search - TradingView
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline - ACCESS Newswire
New CNS Pharmaceuticals (NASDAQ: CNSP) team drives strategic pivot - Stock Titan
CNS Pharma shifts from single cancer focus to hunting new brain and tumor drugs - Stock Titan
Aug Final Week: Can CNS Pharmaceuticals Inc outperform under higher oil prices2026 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
CNS Pharmaceuticals (CNSP) Receives a Buy from Maxim Group - The Globe and Mail
Why is CNS Pharmaceuticals Inc stock going down2025 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
CNSP Earnings History & Surprises | EPS & Revenue Results | CNS PHARMACEUTICALS INC (NASDAQ:CNSP) - ChartMill
9,500 RSUs awarded to CNS Pharmaceuticals (CNSP) CFO - Stock Titan
CNS Pharmaceuticals (CNSP) files insider Form 3 for Chief Financial Officer - Stock Titan
CNSP Financials: Income Statement, Balance Sheet & Cash Flow | CNS Pharmaceuticals - Stock Titan
CNS Pharmaceuticals (CNSP) awards CTO Eric Faulkner 9,500 RSUs - Stock Titan
CNS Pharmaceuticals Appoints New Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals names Lynne Kelley as chief medical officer By Investing.com - Investing.com Australia
CNS Pharmaceuticals (NASDAQ: CNSP) appoints new CMO Lynne Kelley - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints New Executive Leadership Team - Digital Journal
CNS Pharmaceuticals appoints Lynne Kelley as CMO - TipRanks
CNS Pharmaceuticals names Lynne Kelley as chief medical officer - Investing.com
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team - ACCESS Newswire
Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Price Action: Will CNS Pharmaceuticals Inc stock go up in YEARGDP Growth & Smart Investment Allocation Tips - baoquankhu1.vn
Breakout Watch: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Support & Resistance & Verified Technical Trade Signals - baoquankhu1.vn
Is CNS Pharmaceuticals Inc. forming a bullish divergence2025 AllTime Highs & Expert Verified Movement Alerts - mfd.ru
Drug-Delivery Breakthroughs, Cross-Indication Research - GlobeNewswire
Chart Watch: How does CNS Pharmaceuticals Inc perform in inflationary periodsGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
CNS Pharmaceuticals appoints three new executives to leadership team - Investing.com South Africa
CNS Pharmaceuticals appoints three new executives to leadership team By Investing.com - Investing.com Canada
CNS Pharmaceuticals Restructures Finance Leadership, Appoints New CFO - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Investor Outlook: Potential 41.67% Upside Amid Robust CNS Drug Portfolio - DirectorsTalk Interviews
CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO - TipRanks
CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 - marketscreener.com
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Yahoo Finance
Levels Update: Is CNS Pharmaceuticals Inc currently under institutional pressure2025 Performance Recap & Low Risk Growth Stock Ideas - baoquankhu1.vn
Is CNS Pharmaceuticals Inc. currently under institutional pressureFed Meeting & Free Long-Term Investment Growth Plans - mfd.ru
Is CNS Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Sector Review & Risk Managed Investment Strategies - mfd.ru
How CNS Pharmaceuticals Inc. stock performs in weak economy2025 Key Lessons & Stepwise Trade Signal Guides - mfd.ru
What are analysts’ price targets for CNS Pharmaceuticals Inc.July 2025 Opening Moves & Long Hold Capital Preservation Tips - mfd.ru
Why CNS Pharmaceuticals Inc. stock is recommended by analystsInsider Selling & Entry Point Strategy Guides - mfd.ru
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 11.2% – Here’s What Happened - Defense World
Oncotelic Therapeutics, Inc. and Sapu Bioscience Expand - GlobeNewswire
Finanzdaten der Cns Pharmaceuticals Inc-Aktie (CNSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.41%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):